Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
This study has been completed.
Study NCT00416312 Information provided by Sidney Kimmel Comprehensive Cancer Center
First Received on December 27, 2006. Last Updated on May 15, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Additional conditions recognized in this trial
Lymphoma, Large-Cell, Immunoblastic
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
rituximab
computed tomography
positron emission tomography
radionuclide imaging
yttrium Y 90 ibritumomab tiuxetan
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Cadexomer iodine
Iodine
Iodine-131 anti-B1 antibody
More general drug interventions related to this trial
Anti-Infective Agents
Anti-Infective Agents, Local
Antineoplastic Agents
Antirheumatic Agents
Growth Substances
Immunologic Factors
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Trace Elements
Sponsors listed in this trial
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
